Progress in the treatment of Langerhans cell histiocytosis

  • NI Yongan
Expand
  • Department of Pediatrics, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong, China

Received date: 2015-03-15

  Online published: 2015-03-15

Abstract

Treatment of Langerhans cell histiocytosis (LCH) needs to be tailored for each individual patient according to LCH classification currently. Single-system LCH (SS-LCH) has an excellent prognosis. However, there is a poor prognosis in multisystem LCH (MS-LCH) with risk organs (RO) involvement and refractory or recurrent LCH (Re-LCH). The prognosis of MS-LCH with RO involvement and Re-LCH has been improved markedly accompanying with progress of chemotherapy in recent years. The 5-year survival rate of MS-LCH reached above 80%, and the effective rate of Re-LCH reached above 60% after chemotherapy. Re-LCH can be cured by hematopoietic stem cell transplantation.

Cite this article

NI Yongan . Progress in the treatment of Langerhans cell histiocytosis[J]. Journal of Clinical Pediatrics, 2015 , 33(3) : 291 . DOI: 10.3969j.issn.1000-3606.2015.03.023

Outlines

/